V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20218425 | 20175191 | 1.84 | 50 | Palliative (P) | 2019-03-13 | 2019-03-26 | null | 02 | N | CARBOPLATIN + ETOPOSIDE | 101665187 |
| 20218442 | 20175192 | 1.79 | 55 | null | null | 2020-06-07 | Panitumumab | 02 | null | PANITUMUMAB | 100106734 |
| 20218484 | 20175193 | 1.72 | 58.7 | Palliative (P) | 2018-05-02 | 2018-11-14 | NIVOLUMAB | 02 | N | NIVOLUMAB | 100819810 |
| 20218491 | 20175194 | 1.81 | 69.6 | null | 2020-04-09 | 2022-01-30 | ECX | 2 | N | ECX | 101366781 |
| 20218493 | 20175195 | 1.63 | 46 | Adjuvant (A) | null | 2019-03-12 | null | null | N | PANITUMUMAB | 100056429 |
| 20218510 | 20175196 | 1.57 | 57.5 | null | 2017-11-15 | 2017-11-15 | CARBOPLATIN + ETOPOSIDE | 02 | null | CARBOPLATIN + ETOPOSIDE | 100314820 |
| 20218522 | 20175197 | null | 81.4 | Palliative (P) | 2018-10-07 | 2018-10-15 | Carboplatin + Etoposide IV 3 day | 02 | N | CARBOPLATIN + ETOPOSIDE | 100435267 |
| 20218546 | 20175198 | 1.51 | 71.8 | null | 2018-06-18 | 2019-09-28 | Cisplatin +Fluorouracil (3 wk) | 02 | N | CISPLATIN + FLUOROURACIL | 100814559 |
| 20218554 | 20175199 | 1.73 | null | Neo-adjuvant (N) | 2017-03-16 | 2017-04-06 | null | 02 | N | CARBOPLATIN + ETOPOSIDE | 100542741 |
| 20218579 | 20175200 | 1.61 | 81 | null | 2020-04-13 | 2020-04-25 | NIVOLUMAB | 02 | null | NIVOLUMAB | 101507534 |
| 20218596 | 20175201 | 1.55 | 98 | null | 2016-12-27 | 2017-01-12 | ECX | N | null | ECX | 101515166 |
| 20218606 | 20175202 | null | null | Curative (C) | 2019-02-03 | 2019-02-03 | NIVOLUMAB | 02 | null | NIVOLUMAB | 100927037 |
| 20218649 | 20175203 | 1.63 | 88.4 | Neo-adjuvant (N) | 2022-03-23 | 2022-04-20 | Carboplatin + Etoposide IV 3 day | N | N | CARBOPLATIN + ETOPOSIDE | 100631581 |
| 20218650 | 20175204 | null | 84.4 | Neo-adjuvant (N) | null | 2020-11-21 | null | 02 | N | CARBOPLATIN + ETOPOSIDE | 101314823 |
| 20218677 | 20175205 | 1.57 | 140 | null | 2018-10-04 | 2018-10-17 | ECX | 2 | N | ECX | 100423707 |
| 20218703 | 20175206 | 1.9 | 98 | Adjuvant (A) | 2017-01-03 | 2017-01-03 | null | 02 | null | NIVOLUMAB | 101169018 |
| 20218706 | 20175207 | 1.62 | 76.7 | Palliative (P) | null | 2017-08-18 | null | 02 | N | CARBOPLATIN + ETOPOSIDE | 101857138 |
| 20218736 | 20175208 | 1.75 | 79 | Palliative (P) | 2017-07-31 | 2017-07-31 | CISPLATIN + FLUOROURACIL | 02 | N | CISPLATIN + FLUOROURACIL | 100703421 |
| 20218756 | 20175209 | 1.75 | 63.5 | null | 2016-08-04 | 2016-08-20 | ECX | N | null | ECX | 101326076 |
| 20218764 | 20175210 | null | 62.3 | null | 2019-07-29 | 2019-07-30 | NIVOLUMAB | null | null | NIVOLUMAB | 101781052 |
| 20218793 | 20175211 | 1.67 | null | null | 2021-04-17 | 2021-04-29 | Carboplatin + Etoposide iv&po | 02 | null | CARBOPLATIN + ETOPOSIDE | 101440901 |
| 20218807 | 20175212 | 1.8 | 79.5 | Neo-adjuvant (N) | 2016-09-02 | 2016-09-17 | Panitumumab | 02 | N | PANITUMUMAB | 100772723 |
| 20218808 | 20175213 | 1.47 | 82.3 | Neo-adjuvant (N) | 2021-10-07 | 2021-10-08 | null | 02 | N | PANITUMUMAB | 100172881 |
| 20218868 | 20175214 | 1.7 | 101 | Palliative (P) | 2020-02-13 | 2020-03-05 | CISPLATIN + FLUOROURACIL | 02 | null | CISPLATIN + FLUOROURACIL | 101861290 |
| 20218898 | 20175216 | 1.73 | 66.2 | Palliative (P) | 2017-06-16 | 2017-07-03 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101049482 |
| 20218909 | 20175217 | 1.84 | 62 | null | 2017-04-16 | 2018-06-04 | NIVOLUMAB | 02 | N | NIVOLUMAB | 101780442 |
| 20218934 | 20175218 | 1.78 | 90.35 | 03 | null | 2021-12-29 | Panitumumab | 02 | N | PANITUMUMAB | 101756647 |
| 20218942 | 20175219 | 1.76 | 59 | Curative (C) | null | 2019-03-12 | null | 02 | N | CARBOPLATIN + ETOPOSIDE | 100197295 |
| 20218978 | 20175221 | 1.64 | 64.7 | Palliative (P) | 2019-08-26 | 2019-09-06 | null | 2 | N | CARBOPLATIN + ETOPOSIDE | 100886759 |
| 20219015 | 20175223 | 1.72 | null | Palliative (P) | 2018-09-04 | 2018-09-17 | null | null | null | CARBOPLATIN + ETOPOSIDE | 100687325 |
| 20219051 | 20175224 | 1.69 | 95.5 | Curative (C) | 2018-05-04 | 2018-10-22 | null | N | N | ECX | 101650398 |
| 20219081 | 20175225 | 1.56 | 63 | null | 2017-11-17 | 2018-09-15 | null | 2 | null | CISPLATIN + FLUOROURACIL | 100398303 |
| 20219101 | 20175226 | 1.6 | 50.7 | Palliative (P) | null | 2016-06-17 | IRINOTECAN + MDG + PANITUMUMAB | Y | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100193102 |
| 20219158 | 20175227 | 1.73 | 86.9 | Neo-adjuvant (N) | 2018-03-01 | 2018-03-05 | Oxaliplatin + Raltitrexed | 02 | Y | OXALIPLATIN + RALTITREXED | 100698607 |
| 20219163 | 20175228 | 1.55 | 62 | Palliative (P) | 2019-11-12 | 2019-11-12 | EOX | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101715870 |
| 20219184 | 20175229 | 1.81 | 69.35 | Adjuvant (A) | 2020-08-13 | 2020-08-21 | EOX | 2 | N | CAPECITABINE + RT | 100180009 |
| 20219191 | 20175230 | 1.71 | 88.3 | null | 2018-09-08 | 2019-07-14 | Trial Unspecified | N | null | TRIAL | 100164717 |
| 20219230 | 20175231 | 1.76 | 78.1 | Neo-adjuvant (N) | null | 2017-12-24 | IRINOTECAN + MDG + PANITUMUMAB | 02 | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101308545 |
| 20219266 | 20175232 | 1.59 | 63.35 | null | 2016-05-11 | 2016-06-08 | Sorafenib | 2 | null | SORAFENIB | 100529918 |
| 20219290 | 20175233 | 1.76 | 75 | Disease modification (D) | 2017-05-04 | 2017-05-09 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | Y | CETUXIMAB + IRINOTECAN + MDG | 101059105 |
| 20219321 | 20175234 | 1.75 | 45.7 | Palliative (P) | 2022-01-26 | 2022-02-15 | EOX | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101580980 |
| 20219322 | 20175235 | 1.83 | 71.4 | null | 2021-05-05 | 2021-06-17 | EOX | 02 | null | OXALIPLATIN + RALTITREXED | 101850825 |
| 20219337 | 20175236 | 1.7 | 88.3 | null | 2021-05-17 | 2021-05-17 | CAPECITABINE + RT | 2 | null | CAPECITABINE + RT | 100572151 |
| 20219351 | 20175237 | 1.55 | 91 | null | 2018-07-26 | 2018-08-16 | CETUXIMAB + IRINOTECAN + MDG | 2 | null | CETUXIMAB + IRINOTECAN + MDG | 101564360 |
| 20219368 | 20175238 | 1.66 | 59 | null | 2019-04-12 | 2019-05-11 | EOX | 2 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100323023 |
| 20219374 | 20175239 | 1.85 | 79.4 | Neo-adjuvant (N) | null | 2019-09-23 | Oxaliplatin + Raltitrexed | N | Y | OXALIPLATIN + RALTITREXED | 101121897 |
| 20219389 | 20175240 | 1.7 | 62.9 | null | 2016-05-07 | 2016-05-17 | EOX | 02 | null | TRIAL | 100561204 |
| 20219400 | 20175241 | 1.92 | 71 | Palliative (P) | 2018-12-13 | 2020-08-02 | EOX | N | null | CAPECITABINE + RT | 101628008 |
| 20219403 | 20175242 | 1.79 | null | Palliative (P) | 2017-03-30 | 2017-04-19 | Sorafenib | 01 | N | SORAFENIB | 100584316 |
| 20219416 | 20175243 | 1.78 | 60.5 | null | 2017-07-18 | 2017-07-19 | IRINOTECAN + MDG + PANITUMUMAB | N | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101466062 |